PET imaging: Implications for the future of therapy monitoring with PET/CT in oncology

Current Opinion in Pharmacology

Volumn 12, Issue 5, 2012, Pages 569-575

  Tomasi, Giampaolo ^a   Rosso, Lula ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; CHOLINE C 11; FLUCICLATIDE F 18; FLUORODEOXYGLUCOSE F 18; INDICATOR; METHIONINE C 11; TAMOXIFEN; TRACER;

BREAST CANCER; CANCER CELL POPULATION HETEROGENEITY; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; FOLLOW UP; HUMAN; IMAGING; MOLECULAR IMAGING; MONITORING; ONCOLOGICAL PARAMETERS; ONCOLOGY; PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STANDARDIZED UPTAKE VALUE; TEXTURAL FEATURE; THERAPY MONITORING; TREATMENT RESPONSE; TUMOR VOLUME;

HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION ONCOLOGY;

EID: 84867337717     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.07.016     Document Type: Review

References (62)

1. M. Hutchings, and S.F. Barrington PET/CT for therapy response assessment in lymphoma J Nucl Med 50 Suppl 1 2009 21S 30S
2. 18F-FDG PET in assessment of response in non-small cell lung cancer J Nucl Med 50 Suppl 1 2009 31S 42S
3. 18F-FDG PET in colorectal cancer: a systematic review J Nucl Med 50 Suppl 1 2009 43S 54S
4. N. Avril, S. Sassen, and R. Roylance Response to therapy in breast cancer J Nucl Med 50 Suppl 1 2009 55S 63S
5. 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries J Nucl Med 50 Suppl 1 2009 64S 73S
6. H. Schoder, M. Fury, N. Lee, and D. Kraus PET monitoring of therapy response in head and neck squamous cell carcinoma J Nucl Med 50 Suppl 1 2009 74S 88S
7. 18F-FDG PET/CT for assessing response to therapy in esophageal cancer J Nucl Med 50 Suppl 1 2009 89S 96S
8. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response J Nucl Med 50 2009 88 99
9. C. Nanni, L. Fantini, S. Nicolini, and S. Fanti Non FDG PET Clin Radiol 65 2010 536 548
10. M.P. Dunphy, and J.S. Lewis Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET J Nucl Med 50 Suppl 1 2009 106S 121S
11. 11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression Clin Cancer Res 17 2011 7673 7683
12. 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression J Nucl Med 47 2006 763 769
13. 18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 22 Pt 1 2007 6610 6616
14. G. Tomasi, L. Kenny, F. Mauri, F. Turkheimer, and E.O. Aboagye Quantification of receptor-ligand binding with [(18)F]fluciclatide in metastatic breast cancer patients Eur J Nucl Med Mol Imaging 34 2011 1339 1347
15. 18F-annexin V as a PET imaging agent in an animal model of apoptosis J Nucl Med 46 2005 658 666
16. 18F]-labeled isatin sulfonamide Proc Natl Acad Sci USA 106 2009 16375 16380
17. L. Kostakoglu, and P. Valk Assessment of treatment response by FDG-PET Positron Emission Tomography. Clinical Practice 2005 Springer
18. G. Tomasi, F. Turkheimer, and E. Aboagye Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future Mol Imaging Biol 14 2012 131 146
19. R. Boellaard Standards for PET image acquisition and quantitative data analysis J Nucl Med 50 Suppl 1 2009 11S 20S
20. W.A. Weber Use of PET for monitoring cancer therapy and for predicting outcome J Nucl Med 46 2005 983 995
21. M. Vanderhoek, S.B. Perlman, and R. Jeraj Impact of the definition of peak standardized uptake value on quantification of treatment response J Nucl Med 53 2012 4 11
22. L.G. Strauss, D. Koczan, S. Klippel, L. Pan, C. Cheng, U. Haberkorn, S. Willis, and A. Dimitrakopoulou-Strauss Impact of cell-proliferation-associated gene expression on 2-deoxy-2-[(18)F]fluoro-d-glucose (FDG) kinetics as measured by dynamic positron emission tomography (dPET) in colorectal tumors Mol Imaging Biol 13 2011 1290 1300
23. A.A. Lammertsma, C.J. Hoekstra, G. Giaccone, and O.S. Hoekstra How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging 33 Suppl 1 2006 16 21
24. P. Cheebsumon, L.M. Velasquez, C.J. Hoekstra, W. Hayes, R.W. Kloet, N.J. Hoetjes, E.F. Smit, O.S. Hoekstra, A.A. Lammertsma, and R. Boellaard Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis Eur J Nucl Med Mol Imaging 38 2011 832 842
25. G. Tomasi, S. Kimberley, L. Rosso, E. Aboagye, and F. Turkheimer Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology Phys Med Biol 57 2012 1889 1906
26. L. Rosso, C.S. Brock, J.M. Gallo, A. Saleem, P.M. Price, F.E. Turkheimer, and E.O. Aboagye A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients Cancer Res 69 2009 120 127
27. H. Zaidi, M. Abdoli, C.L. Fuentes, and I.M. El Naqa Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma Eur J Nucl Med Mol Imaging 39 2012 881 891
28. 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas J Neurooncol 71 2005 325 332
29. 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma Ann Surg Oncol 17 2010 115 122
30. 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology Eur J Nucl Med Mol Imaging 38 2011 1191 1202
31. B.N. Tang, N. Sadeghi, F. Branle, O. De Witte, D. Wikler, and S. Goldman Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma J Neurooncol 71 2005 161 168
32. H. Yu, C. Caldwell, K. Mah, and D. Mozeg Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning IEEE Trans Med Imaging 28 2009 374 383
33. 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer J Nucl Med 52 2011 369 378
34. B. Ganeshan, S. Abaleke, R. Young, C. Chatwin, and K. Miles Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage Cancer Imaging 2010 137 143
35. V. Goh, B. Ganeshan, P. Nathan, J.K. Juttla, A. Vinayan, and K.A. Miles Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker Radiology 261 2011 165 171
36. D. Assefa, H. Keller, C. Menard, N. Laperriere, R.J. Ferrari, and I. Yeung Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation Med Phys 37 2010 1722 1736
37. I. El Naqa, P. Grigsby, A. Apte, E. Kidd, E. Donnelly, D. Khullar, S. Chaudhari, D. Yang, M. Schmitt, and R. Laforest Exploring feature-based approaches in PET images for predicting cancer treatment outcomes Pattern Recognit 42 2009 1162 1171
38. A. Dimitrakopoulou-Strauss, M. Hoffmann, R. Bergner, M. Uppenkamp, U. Haberkorn, and L.G. Strauss Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET Clin Nucl Med 34 2009 576 584
39. 18F-FDG uptake as a predictor of patient outcome J Nucl Med 49 2008 1973 1979
40. 18F-FDG PET J Nucl Med 53 2012 693 700
41. P.E. Galavis, C. Hollensen, N. Jallow, B. Paliwal, and R. Jeraj Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters Acta Oncol 49 2010 1012 1016
42. H. Yu, C. Caldwell, K. Mah, I. Poon, J. Balogh, R. MacKenzie, N. Khaouam, and R. Tirona Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images Int J Radiat Oncol Biol Phys 75 2009 618 625
43. M. Vaidya, K.M. Creach, J. Frye, F. Dehdashti, J.D. Bradley, and I. El Naqa Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer Radiother Oncol 102 2012 239 245
44. J. Willaime, F. Turkheimer, L. Kenny, and E. Aboagye Image descriptors of intra-tumor proliferative heterogeneity predict chemotherapy response in breast tumors J Nucl Med Meeting Abstracts 53 1-MeetingAbstracts 2012 387
45. 18F] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma Clin Cancer Res 13 2007 3552 3558
46. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors J Nucl Med 51 2010 866 874
47. 18F]- 3′Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel Clin Cancer Res 17 2011 7664 7672
48. 18F]fluorothymidine positron emission tomography Eur J Nucl Med Mol Imaging 34 2007 1339 1347
49. B.S. Pio, C.K. Park, R. Pietras, W.A. Hsueh, N. Satyamurthy, M.D. Pegram, J. Czernin, M.E. Phelps, and D.H. Silverman Usefulness of 3′-[F-18] fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy Mol Imaging Biol 8 2006 36 42
50. B. Kasper, G. Egerer, M. Gronkowski, S. Haufe, T. Lehnert, M. Eisenhut, G. Mechtersheimer, A.D. Ho, and U. Haberkorn Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET Leuk Lymphoma 48 2007 746 753
51. C. Kobe, M. Scheffler, A. Holstein, T. Zander, L. Nogova, A.A. Lammertsma, R. Boellaard, B. Neumaier, R.T. Ullrich, and M. Dietlein Predictive value of early and late residual (18)F-fluorodeoxyglucose and (18)F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib Eur J Nucl Med Mol Imaging 39 2012 1117 1127
52. 18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 2007 4714 4721
53. 18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer Eur J Nucl Med Mol Imaging 34 2007 878 883
54. F. Dehdashti, P.W. Grigsby, J.S. Lewis, R. Laforest, B.A. Siegel, and M.J. Welch Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) J Nucl Med 49 2008 201 205
55. D.W. Dietz, F. Dehdashti, P.W. Grigsby, R.S. Malyapa, R.J. Myerson, J. Picus, J. Ritter, J.S. Lewis, M.J. Welch, and B.A. Siegel Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study Dis Colon Rectum 51 2008 1641 1648
56. J.G. Rajendran, D.L. Schwartz, J. O'Sullivan, L.M. Peterson, P. Ng, J. Scharnhorst, J.R. Grierson, and K.A. Krohn Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin Cancer Res 12 2006 5435 5441
57. 18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients Radiother Oncol 80 2006 151 156
58. 18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival Clin Cancer Res 14 2008 2623 2630
59. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
60. F. Dehdashti, J.E. Mortimer, K. Trinkaus, M.J. Naughton, M. Ellis, J.A. Katzenellenbogen, M.J. Welch, and B.A. Siegel PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer Breast Cancer Res Treat 113 2009 509 517
61. 11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma J Neurosurg 103 2005 498 507
62. 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy J Nucl Med 49 2008 694 699